Clinical practice guidelines and conflict of interest.
出版信息
CMAJ. 2005 Nov 22;173(11):1297, 1299. doi: 10.1503/cmaj.051423.
Abstract
摘要
相似文献
1
Clinical practice guidelines and conflict of interest.临床实践指南与利益冲突。
CMAJ. 2005 Nov 22;173(11):1297, 1299. doi: 10.1503/cmaj.051423.
2
Long-acting insulin analogs versus human insulins.长效胰岛素类似物与人胰岛素的比较。
Diabetes Technol Ther. 2008 Oct;10(5):331-2. doi: 10.1089/dia.2008.0071.
3
Insulin glargine: a new basal insulin analogue.甘精胰岛素：一种新型基础胰岛素类似物。
QJM. 2002 Nov;95(11):757-61. doi: 10.1093/qjmed/95.11.757.
4
Insulin glargine clinical trials.甘精胰岛素临床试验。
Clin Ther. 2004 Jul;26(7):1179-81; discussion 1182-3. doi: 10.1016/s0149-2918(04)90190-7.
5
Modelling cost effectiveness of insulin glargine for the treatment of type 1 and 2 diabetes in Canada.加拿大甘精胰岛素治疗1型和2型糖尿病的成本效益建模
Pharmacoeconomics. 2007;25(3):253-66. doi: 10.2165/00019053-200725030-00007.
6
New Long-Acting Basal Insulins: Does Benefit Outweigh Cost?新型长效基础胰岛素：益处是否大于成本？
Diabetes Care. 2016 Aug;39 Suppl 2:S172-9. doi: 10.2337/dcS15-3011.
7
Modeling the lifetime costs of insulin glargine and insulin detemir in type 1 and type 2 diabetes patients in Canada: a meta-analysis and a cost-minimization analysis.对加拿大 1 型和 2 型糖尿病患者使用甘精胰岛素和地特胰岛素的终生成本进行建模：荟萃分析和成本最小化分析。
J Med Econ. 2011;14(2):207-16. doi: 10.3111/13696998.2011.561390. Epub 2011 Mar 2.
8
Insulin Glargine: a review 8 years after its introduction.甘精胰岛素：上市8年后的综述
Expert Opin Pharmacother. 2009 Mar;10(4):705-18. doi: 10.1517/14656560902775677.
9
Optimizing glycemic control with insulin glargine.使用甘精胰岛素优化血糖控制。
Diabetes Technol Ther. 2003;5(3):471-3. doi: 10.1089/152091503765692009.
10
Cost effectiveness of insulin glargine plus oral antidiabetes drugs compared with premixed insulin alone in patients with type 2 diabetes mellitus in Canada.加拿大 2 型糖尿病患者中甘精胰岛素联合口服抗糖尿病药物与预混胰岛素单独治疗的成本效果比较。
Appl Health Econ Health Policy. 2010;8(4):267-80. doi: 10.2165/11535380-000000000-00000.
引用本文的文献
1
Conflicts of interest in clinical guidelines, advisory committee reports, opinion pieces, and narrative reviews: associations with recommendations.临床指南、顾问委员会报告、观点文章和叙述性评论中的利益冲突：与建议的关联。
Cochrane Database Syst Rev. 2020 Dec 8;12(12):MR000040. doi: 10.1002/14651858.MR000040.pub3.
2
Canadian Association of Gastroenterology policy on the application for, and implementation of, clinical practice guidelines.加拿大胃肠病学会关于临床实践指南的申请和实施的政策。
Can J Gastroenterol Hepatol. 2014 Oct;28(9):473-80. doi: 10.1155/2014/680829.
3
Guideline standardisation, cost effectiveness, industry needs and conflict of interest.指南标准化、成本效益、行业需求与利益冲突。
Mens Sana Monogr. 2007 Jan;5(1):56-78. doi: 10.4103/0973-1229.32150.
4
Clinical practice guidelines and industry.临床实践指南与行业
Mens Sana Monogr. 2007 Jan;5(1):44-55. doi: 10.4103/0973-1229.32149.
5
Competing interests in development of clinical practice guidelines for diabetes management: Report from a multidisciplinary workshop.利益冲突在糖尿病管理临床实践指南的制定中：多学科研讨会的报告。
J Multidiscip Healthc. 2008 May 1;1:29-34. doi: 10.2147/jmdh.s3553.
6
AGREEing on Canadian cardiovascular clinical practice guidelines.就加拿大心血管临床实践指南达成一致意见。
Can J Cardiol. 2008 Oct;24(10):753-7. doi: 10.1016/s0828-282x(08)70679-2.
7
Moving from opacity to transparency in pharmaceutical policy.推动药品政策从不透明走向透明。
CMAJ. 2008 Feb 12;178(4):428-31. doi: 10.1503/cmaj.070799.
8
Public involvement in guideline development.公众参与指南制定。
CMAJ. 2007 Apr 24;176(9):1308-9. doi: 10.1503/cmaj.1060241.
9
Evidence and advocacy: are all things considered?证据与宣传：是否考虑了所有因素？
CMAJ. 2006 Jun 20;174(13):1856. doi: 10.1503/cmaj.060231.
10
The Canadian Hypertension Education Program--a unique Canadian initiative.加拿大高血压教育项目——一项独特的加拿大倡议。
Can J Cardiol. 2006 May 15;22(7):559-64. doi: 10.1016/s0828-282x(06)70277-x.
本文引用的文献
1
Canadian Diabetes Association 2013 clinical practice guidelines for the prevention and management of diabetes in Canada. Introduction.加拿大糖尿病协会2013年加拿大糖尿病预防与管理临床实践指南。引言。
Can J Diabetes. 2013 Apr;37 Suppl 1:S1-3. doi: 10.1016/j.jcjd.2013.01.009. Epub 2013 Mar 26.
2
Conflicts of interests and investments.利益冲突与投资
CMAJ. 2004 Nov 23;171(11):1313. doi: 10.1503/cmaj.1041686.
3
Cash interests taint drug advice.金钱利益玷污药物建议。
Nature. 2005 Oct 20;437(7062):1070-1. doi: 10.1038/4371070a.
Zotero 插件